Finance

Lists
SABS:NASDAQ
SAB Biotherapeutics Inc
$3.10
-0.16%
(-0.0050) 1D
Nov 12, 9:34:53 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
$3.10
High
$3.10
Low
$3.10
Mkt. cap
279.73M
Avg. vol.
644.07K
Volume
13.00
52-wk high
$5.15
52-wk low
$2.44
EPS
-$0.93
Beta
0.67
Shares outstanding
90.09M
No. of employees
86
Open
$3.10
High
$3.10
Low
$3.10
Mkt. cap
279.73M
Avg. vol.
644.07K
Volume
13.00
52-wk high
$5.15
52-wk low
$2.44
EPS
-$0.93
Beta
0.67
Shares outstanding
90.09M
No. of employees
86
About SAB Biotherapeutics Inc
CEO-
Employees86
Founded2014
HeadquartersMiami Beach, Florida, United States
SectorHealth Care
IndustryBiotechnology
Websitesab.bio
Analyst ratings
Based on 4 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current $3.10
$15.00 (+383.09%)
Average
$13.25 (+326.73%)
Lowest
$11.00 (+254.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Oppenheimer
Buy
Reiterated
$14.00
+350.9%
11/06/2026
Samantha Semenkow
Citi
Buy
Maintained
$11.00
+254.3%
11/05/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$15.00
+383.1%
11/05/2026
Eliana Merle
Barclays
Buy
Maintained
$13.00
+318.7%
11/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$10.00
+222.1%
08/06/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
$16.00
+415.3%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$6.00
+93.2%
06/16/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$14.00
+350.9%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
$11.00
+254.3%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$15.00
+383.1%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$13.00
+318.7%
04/02/2026
Michael Yee
UBS
Buy
Maintained
$7.00
+125.4%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
9.73M
13.40M
16.17M
18.08M
Cost of revenue
9.73M
13.40M
16.17M
18.08M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.04M
6.60M
7.20M
7.82M
Operating expense
6.04M
6.60M
7.20M
7.82M
Total operating expenses
15.77M
20.00M
23.38M
25.90M
Operating income
-15.77M
-20.00M
-23.38M
-25.90M
Other non operating income
-1.73M
144.40K
-761.00K
1.99M
EBT including unusual items
-16.86M
-18.87M
-22.49M
-22.30M
EBT excluding unusual items
-16.86M
-18.87M
-22.49M
-22.30M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16.86M
-18.87M
-22.49M
-22.30M
Net profit margin
-
-
-
-
Earnings per share
-0.41
-
-0.28
-0.26
Interest and investment income
700.74K
1.05M
1.71M
1.61M
Interest expense
-63.46K
-62.74K
-62.00K
-
Net interest expenses
637.28K
984.45K
1.65M
1.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.01M
-19.25M
-22.54M
-25.08M
Gain or loss from assets sale
-
-
-
-66.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps